None
NEW YORK - Wall Street’s main indexes closed lower on Dec 10 as investors anxiously awaited key inflation reports that could influence the Federal Reserve’s interest rate decision next week. Among the S&P 500‘s 11 major industry sectors, communication services was the biggest boost with help from a rally in shares of Google-parent Alphabet after it unveiled a new chip. The biggest drag was from technology, pressured by a sell-off in Oracle shares after the cloud computing company missed Wall Street estimates for second-quarter results. Also weighing on technology was a sell-off in chips after China announced on Dec 9 an investigation into Nvidia over suspected violations of the country’s anti-monopoly law. The probe was widely seen as retaliation against Washington’s latest curbs on the Chinese chip sector. According to preliminary data, the S&P 500 lost 16.53 points, or 0.27 per cent, to end at 6,036.32 points, while the Nasdaq Composite lost 49.45 points, or 0.25 per cent, to 19,687.24. The Dow Jones Industrial Average fell 143.46 points, or 0.32 per cent, to 44,259.60. A November reading of the Consumer Price Index, due on Dec 11, is among the last major reports ahead of the Fed’s Dec 17-18 meeting. Headline inflation is expected to have risen slightly in November to 2.7 per cent from 2.6 per cent in October. The Producer Price Index report will follow on Dec 12. “There’s a little bit of wait-and-see in the market ahead of the CPI and PPI data this week,” said Ms Mona Mahajan, head of investment strategy at Edward Jones. “Markets want to see a number that won’t be too disruptive to the Fed next week.” If the CPI comes in line with estimates, investors will expect an “all clear” for the Fed to lower rates by 25 basis points next week, she added. Traders see an 86 per cent chance for a cut next week, CME’s FedWatch Tool showed. Bets had jumped after news on Dec 6 of an uptick in unemployment along with a rebound in job growth, which had slowed in October. Noting the S&P 500‘s roughly 27 per cent gain for the year so far, Ms Lindsey Bell, chief strategist at 248 Ventures in Charlotte, North Carolina, said investors are cautious ahead of the economic data and Fed meeting. “We’re in a seasonally strong period of the year and investors are just kind of taking a breather,” said Ms Bell. Market participants will be watching out for signs that the US central bank will pause its easing cycle in January, after a host of Fed officials last week hinted at a slower pace of monetary policy easing on the back of a resilient economy. “It’s less about what the Fed does next week but what they say about the future trajectory of interest rates,” said Ms Bell. Among individual stock movers, software firm MongoDB lost ground despite raising its forecast for annual results. Shares in Walgreens Boots Alliance rallied after reports that it is in talks to sell itself to private equity firm Sycamore Partners. Alaska Airlines shares rose as it raised its fourth-quarter profit forecast, while Boeing gained ground after Reuters reported the planemaker restarted production of its 737 Max jets last week. Luxury homebuilder Toll Brothers shares fell after its quarterly results beat expectations but its current quarter forecasts disappointed. REUTERSPresident-elect Donald Trump has promised swift immigration action during his second term in office. He has repeatedly pledged to seal the U.S.-Mexico border and implement a mass deportation program targeting millions of people who are in the U.S. illegally. On Dec. 8, in a wide-ranging interview with NBC’s “Meet the Press,” Trump suggested he is considering deporting entire families, including children who are U.S. citizens with undocumented parents. “I don’t want to be breaking up families, so the only way you don’t break up the family is you keep them together and you have to send them all back,” Trump said, echoing remarks his border czar Tom Homan made in October. Multiple people on social media claim the president cannot legally deport U.S. citizens because doing so would be unconstitutional. Recent online search trends show many people online are wondering if this is true. THE QUESTION Is it unconstitutional to deport U.S. citizens? THE SOURCES 14th Amendment of the U.S. Constitution Afroyim v. Rusk Michelle Mittelstadt , director of communications and public affairs for the Migration Policy Institute Allen Orr, Jr., J.D. , an immigration attorney and founder of Orr Immigration Law Firm P.C. Jean Lantz Reisz, J.D. , co-director of the USC Immigration Clinic, and clinical associate professor of law at the USC Gould School of Law Maureen Sweeney, J.D. , law school professor and director of the Chacón Center for Immigrant Justice at the University of Maryland Francis King Carey School of Law Scott D. Pollock & Associates, P.C , an immigration law firm in Chicago, Illinois THE ANSWER Yes, deporting U.S. citizens is a violation of the U.S. Constitution. Sign up for the VERIFY Fast Facts daily Newsletter! WHAT WE FOUND The president cannot deport U.S. citizens, including those with undocumented parents, because doing so would be unconstitutional, according to immigration law experts. The U.S. Constitution protects natural-born citizens from being deported by the government. But citizens may choose to renounce their citizenship voluntarily. “It is unconstitutional to deport U.S. citizens,” said Michelle Mittelstadt, a spokesperson for the nonpartisan Migration Policy Institute. U.S. citizenship through birth, which is known as “birthright citizenship,” comes via the 14th Amendment , which was ratified after the Civil War to secure citizenship for newly freed Black Americans. It was later, after multiple court challenges, used to guarantee citizenship to all babies born on U.S. soil regardless of the citizenship of their parents. Section 1 of the 14th Amendment reads: “All persons born or naturalized in the United States, and subject to the jurisdiction thereof, are citizens of the United States and of the State wherein they reside. No State shall make or enforce any law which shall abridge the privileges or immunities of citizens of the United States; nor shall any State deprive any person of life, liberty, or property, without due process of law; nor deny to any person within its jurisdiction the equal protection of the laws.” Trump has repeatedly said he would attempt to end birthright citizenship through executive action in his second term. However, we previously found that the president cannot end birthright citizenship by executive order because it would also violate the Constitution. Amending the Constitution would require congressional action and ratification by three-quarters of the states. Law experts agree that any executive order by Trump or any president to terminate birthright citizenship would likely be subjected to legal and judicial challenges. On Dec. 8, immigration attorney Allen Orr Jr. wrote on X that a president cannot deport U.S. citizens because “U.S. citizenship cannot be revoked arbitrarily” under the 14th Amendment. Orr added that in 1967, the U.S. Supreme Court ruled in a landmark case known as Afroyim v. Rusk “that the government cannot involuntarily strip a citizen of their citizenship, meaning a person can only lose their citizenship if they voluntarily relinquish it.” Jean Reisz, a law professor and the co-director of the USC Immigration Clinic, told VERIFY it is unclear if Trump actually plans to forcefully deport U.S. citizens with undocumented parents, which she agrees he cannot legally do because it would be unlawful. “It seems to me Trump is addressing a situation that often occurs in mixed-status families with young U.S. citizen or LPR [legal permanent resident] children, and/or spouses where a noncitizen family member is going to be deported and the family must decide whether they will go with the noncitizen to the country to where the noncitizen is being deported and start a life there, or stay in the U.S. and be separated from the noncitizen,” Reisz explained. VERIFY reached out to the Trump transition team for clarification but did not hear back before publication. Although deporting U.S. citizens is unconstitutional, it has happened illegally in the past, according to Mittelstadt and Maureen Sweeney, the director of the Chacón Center for Immigrant Justice at the University of Maryland Francis King Carey School of Law. “U.S. citizens have been deported, unlawfully, during prior instances of significant deportations, including during local ‘repatriation drives’ that took place around the U.S. during the Great Depression and during ‘Operation Wetback ’ in the Eisenhower administration,” Mittelstadt said. “These deportations were illegal then, as they would be now,” Sweeney noted. The Associated Press contributed to this report . Related Articles No, the president cannot end birthright citizenship by executive order Yes, Trump will have the authority to pardon Jan. 6 rioters What we can VERIFY about Trump’s plan to use the military to support mass deportations The VERIFY team works to separate fact from fiction so that you can understand what is true and false. Please consider subscribing to our daily newsletter , text alerts and our YouTube channel . You can also follow us on Snapchat , Instagram , Facebook and TikTok . Learn More » Follow Us YouTube Snapchat Instagram Facebook TikTok Want something VERIFIED? Text: 202-410-8808Liberal MP accuses opposition MPs of wasting time on another Boissonnault probeNone
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen AMGN today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.One of the bigger drivers of Medicaid’s rising costs in Virginia is the ballooning expense of covering weight-loss drugs, a state Senate Finance Committee review found. That cost climbed to $267.8 million for the fiscal year that ended June 30, more than three times the bill from when Virginia Medicaid began covering the increasingly commonly prescribed medications two years earlier, senior legislative analyst Mike Tweedy told the committee at its annual retreat at the Hotel Madison in Harrisonburg. But when the state Department of Medical Assistance Services added coverage of the new weight-loss drugs in November 2022, decision-makers had no information about the fiscal impact, he said. About 30 states cover the medications. With the federal Centers for Disease Control and Prevention’s view that obesity has become a major public health issue and as regulators consider authorizing use of the drugs for other conditions, the new medications look set to put still more upward pressure on Medicaid costs, Tweedy said. The injectable drug Ozempic costs patients in the U.S. $969 a month, more than six times the Canadian price. The managed care plans that cover most of Virginia Medicaid’s patients began reporting significant price increases to Medicaid officials in late spring last year. The drugs are expensive, and Americans pay more for them than people in other countries do, according to a U.S. Senate Health Education and Pensions Committee study. Ozempic costs diabetic patients in the States $969 a month, more than six times the Canadian price, while Wegovy costs Americans using it to treat obesity $1,349 a month, or more than 14 times the price in Great Britain. Tweedy said the standards for when and how the department pays for the medications is one area where it needs to focus on cost effectiveness and controlling spending growth. Another is emergency room payments. Medicaid’s payments for ER care have increased 15% a year for the past two years, Tweedy said. The state last year lost a federal court case challenging a longstanding policy toward cutting Medicaid payments to emergency room physicians if a patient came to the ER with a nonemergency, paying instead as if the doctors performed more routine care. While the General Assembly approved a new program last year, Medicaid has not implemented the program, Tweedy said. Policymakers and insurers have long tried to rein in claims for unnecessary ER visits, arguing that they are one reason why U.S. health care costs are so much higher than in other nations. One reason why many Medicaid patients may be turning to emergency rooms for treatment is that Medicaid, unlike commercial insurance, does not require the people it covers — basically low-income families and adults as well as people with severe disabilities — to pay for part of the cost out of pocket, Tweedy said. They often don't feel there are other available options for care, either. One approach some hospitals have started using — setting up urgent care clinics near their ERs in order to triage care — is less common in urban areas where many Medicaid recipients live, he said. Virginia Medicaid is facing an unusual need for additional funds this year and next than the current budget for those years set aside: some $632.4 million. One reason for that is a $160 million shortfall Medicaid saw at the June 30 end of the last fiscal year, mainly because the post-pandemic decline in enrollment happened more slowly than expected, Tweedy told the committee. Others include a projected $289.7 million increase in fee for service payments, a $36.2 million increase in managed care rates, a $61.7 million increase in supplemental payments to hospitals and $59.2 million for Indian Health Clinics to cover specified nontribal costs. In addition, increased payments to Medicare — the federal insurance program for people ages 65 or older and people with certain disabilities — and pharmacy rebates are pushing up Medicaid costs. Dave Ress (804) 649-6948 dress@timesdispatch.com Stay up-to-date on the latest in local and national government and political topics with our newsletter.Jack Sawyer's Emotional Outburst After Michigan Brawl Captures Attention
Empowered Funds LLC Purchases 10,711 Shares of Bath & Body Works, Inc. (NYSE:BBWI)EAST LANSING, Mich. — The sight was a common one for Andrew Kolpacki. For many a Sunday, he would watch NFL games on TV and see quarterbacks putting their hands on their helmets, desperately trying to hear the play call from the sideline or booth as tens of thousands of fans screamed at the tops of their lungs. When the NCAA's playing rules oversight committee this past spring approved the use of coach-to-player helmet communications in games for the 2024 season, Kolpacki, Michigan State's head football equipment manager, knew the Spartans' QBs and linebackers were going to have a problem. "There had to be some sort of solution," he said. As it turns out, there was. And it was right across the street. Kolpacki reached out to Tamara Reid Bush, a mechanical engineering professor who not only heads the school's Biomechanical Design Research Laboratory but also is a football season ticket-holder. Kolpacki "showed me some photos and said that other teams had just put duct tape inside the (earhole), and he asked me, 'Do you think we can do anything better than duct tape,?" Bush said. "And I said, 'Oh, absolutely.'" Bush and Rylie DuBois, a sophomore biosystems engineering major and undergraduate research assistant at the lab, set out to produce earhole inserts made from polylactic acid, a bio-based plastic, using a 3D printer. Part of the challenge was accounting for the earhole sizes and shapes that vary depending on helmet style. Once the season got underway with a Friday night home game against Florida Atlantic on Aug. 30, the helmets of starting quarterback Aidan Chiles and linebacker Jordan Turner were outfitted with the inserts, which helped mitigate crowd noise. DuBois attended the game, sitting in the student section. "I felt such a strong sense of accomplishment and pride," DuBois said. "And I told all my friends around me about how I designed what they were wearing on the field." All told, Bush and DuBois have produced around 180 sets of the inserts, a number that grew in part due to the variety of helmet designs and colors that are available to be worn by Spartan players any given Saturday. Plus, the engineering folks have been fine-tuning their design throughout the season. Dozens of Bowl Subdivision programs are doing something similar. In many cases, they're getting 3D-printed earhole covers from XO Armor Technologies, which provides on-site, on-demand 3D printing of athletic wearables. The Auburn, Alabama-based company has donated its version of the earhole covers to the equipment managers of programs ranging from Georgia and Clemson to Boise State and Arizona State in the hope the schools would consider doing business with XO Armor in the future, said Jeff Klosterman, vice president of business development. XO Armor first was approached by the Houston Texans at the end of last season about creating something to assist quarterback C.J. Stroud in better hearing play calls delivered to his helmet during road games. XO Armor worked on a solution and had completed one when it received another inquiry: Ohio State, which had heard Michigan State was moving forward with helmet inserts, wondered if XO Armor had anything in the works. "We kind of just did this as a one-off favor to the Texans and honestly didn't forecast it becoming our viral moment in college football," Klosterman said. "We've now got about 60 teams across college football and the NFL wearing our sound-deadening earhole covers every weekend." The rules state that only one player for each team is permitted to be in communication with coaches while on the field. For the Spartans, it's typically Chiles on offense and Turner on defense. Turner prefers to have an insert in both earholes, but Chiles has asked that the insert be used in only one on his helmet. Chiles "likes to be able to feel like he has some sort of outward exposure," Kolpacki said. Exposure is something the sophomore signal-caller from Long Beach, California, had in away games against Michigan and Oregon this season. Michigan Stadium welcomed 110,000-plus fans for the Oct. 26 matchup between the in-state rivals. And while just under 60,000 packed Autzen Stadium in Eugene, Oregon, for the Ducks' 31-10 win over Michigan State three weeks earlier, it was plenty loud. "The Big Ten has some pretty impressive venues," Kolpacki said. "It can be just deafening," he said. "That's what those fans are there for is to create havoc and make it difficult for coaches to get a play call off." Something that is a bit easier to handle thanks to Bush and her team. She called the inserts a "win-win-win" for everyone. "It's exciting for me to work with athletics and the football team," she said. "I think it's really exciting for our students as well to take what they've learned and develop and design something and see it being used and executed." Get local news delivered to your inbox!
SAN ANTONIO (AP) — Primo Spears' 31 points led UTSA over Houston Christian 78-71 on Saturday night. Spears had five assists for the Roadrunners (3-3). Raekwon Horton added 19 points while shooting 6 of 7 from the field and 7 for 7 from the line while he also had nine rebounds. Damari Monsanto finished 3 of 8 from 3-point range to finish with 11 points. Julian Mackey finished with 20 points for the Huskies (2-6). Bryson Dawkins added 16 points and two blocks for Houston Christian. Demari Williams also had 11 points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Percentages: FG .441, FT .667. 3-Point Goals: 8-25, .320 (McCottry 2-2, Davis 2-11, Thompson 1-1, Butler 1-2, Doby 1-3, Jervier 1-3, I.Ross 0-1, Marius 0-2). Team Rebounds: 0. Team Turnovers: None. Blocked Shots: 4 (McCottry 2, Butler, Consorte). Turnovers: 7 (Butler 2, McCottry 2, Consorte, Doby, Marius). Steals: 7 (McCottry 3, Doby 2, Butler, Marius). Technical Fouls: None. Percentages: FG .500, FT .615. 3-Point Goals: 13-33, .394 (Henderson 5-8, Skobalj 3-6, Jackson 2-7, Pickett 2-7, Ciani 1-1, Freeman 0-4). Team Rebounds: 3. Team Turnovers: None. Blocked Shots: 5 (Ciani 2, Henderson, Jackson, Skobalj). Turnovers: 10 (Henderson 3, Jackson 2, Pickett 2, Freeman, Jeffries, Kancleris). Steals: 4 (Pickett 2, Jeffries, Kancleris). Technical Fouls: None. .
Idaho execution costs, challenges persist as state’s $100,000 lethal injection drugs expireST. PAUL – Hunting pheasants, ruffed grouse, squirrels or rabbits offers Minnesota hunters opportunities to continue enjoying the outdoors as temperatures fall and snow blankets the landscape, the Department of Natural Resources said. Here’s a look at season dates for the small game species. Fisher, martin and bobcat trapping opens Saturday, Dec. 14, so hunters should be aware of the potential for additional traps in the woods. Hunters can find regulations and complete bag limit information on the DNR website at mndnr.gov/hunting . More information about how or where to hunt can be found on the DNR’s learn to hunt webpages at mndnr.gov/gohunting . Recorded webinars with tips on how to hunt pheasants, grouse, squirrels or rabbits are available in the webinar archive on the outdoor skills and stewardship page of the Minnesota DNR website at www.mndnr.gov/discover .
Mutual of America Capital Management LLC reduced its position in shares of Masimo Co. ( NASDAQ:MASI – Free Report ) by 6.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,865 shares of the medical equipment provider’s stock after selling 1,667 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Masimo were worth $3,182,000 as of its most recent SEC filing. Several other hedge funds also recently modified their holdings of the company. NBC Securities Inc. lifted its holdings in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC boosted its position in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 200 shares during the last quarter. HHM Wealth Advisors LLC raised its holdings in shares of Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after purchasing an additional 125 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its stake in Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 573 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Several research analysts have issued reports on MASI shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company boosted their price objective on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Piper Sandler lifted their target price on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $167.00. Masimo Stock Performance MASI stock opened at $172.96 on Friday. The firm has a 50 day simple moving average of $142.28 and a 200 day simple moving average of $127.76. Masimo Co. has a 52 week low of $91.60 and a 52 week high of $174.34. The stock has a market cap of $9.26 billion, a P/E ratio of 119.28 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo ( NASDAQ:MASI – Get Free Report ) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the previous year, the company posted $0.63 EPS. Masimo’s revenue was up 5.4% on a year-over-year basis. Research analysts anticipate that Masimo Co. will post 4.04 earnings per share for the current fiscal year. About Masimo ( Free Report ) Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. Further Reading Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. ( NASDAQ:MASI – Free Report ). Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter .
Donald Trump is returning to the world stage. So is his trollingWhy EV Stocks Lucid Motors, QuantumScape, and Navitas Semiconductor Rocketed Higher Today